The share price of4DPharma(LSE: DDDD) a pharmaceutical company that focuses on significant new therapeutic areas is up 9.5% so far today, following publication of a research update.
The update concerns two of 4D Pharmas products Blautix, which is atreatment for irritable bowel syndrome (IBS), and Thetanix, which is for the treatment of Paediatric Crohns Disease (PCD).Both productsare live biotherapeutics, which use live bacteria as the active agent, rather than either of the more traditional approaches of chemicals or biological agents, such as antibodies.
The company says that both Blautix and Thetanix are now anticipated to enter clinical studies in Q2 2015. The studies will primarily be concerned, 4D Pharma says, with evaluating the safety and tolerability of the two products.
In addition,some clinical effects ofBlautix would be assessed in bothin healthy volunteers and a small number of symptomatic IBS individuals, whilstsome clinical effects ofThetanixwould be assessed in PCD patients.
Commenting on the update,Alex Stevenson,the companys chief scientific officer, commented:
The Blautix and Thetanix trials will represent important milestones for the Company and a new class of therapeutic, designed to treat the underlying causes of diseases rather than just the symptoms. In addition, 4D continues to generate a strong pipeline of live biotherapeutics for other important diseases, using its proprietary MicroRx platform.
At 304p, 4D Pharmas share price is currently up close to 70%since it listed on AIM in February of this year, since which time the AIM All-Share has fallen over 11%, and the FTSE All-Share has remained flat.
If you’re looking foragreat long-term growth opportunity, you’ll want to get hold of The Motley Fool’s exclusive “Top Growth Share“report.
Our expect analysts have found aninnovative companythat they think is really exciting.
To find out the company’s name getyour FREE copyof theno-obligationreportnow!
Jon Wallis has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
